期刊文献+

眼动检测与齐拉西酮胶囊治疗精神分裂症疗效的相关性

下载PDF
导出
摘要 目的研究眼动检测(DEM2000)与精神分裂症疗效的相关性。方法:对18例以阴性症状为主(阴性组),25例以阳性症状为主(阳性组),20例以其它精神分裂症为主(混合组)的患者均使用齐拉西酮治疗8周,另28名正常人(对照组)进行眼动检测OEM2000),凝视点数(NEF),反应探索分(RSS)及判别分析值①分)的测查。结果:与治疗前比较,齐拉西酮治疗精神分裂症组PANSS评分均有显著改善(t=10.83,P〈0.01);治疗前后认知功能比较,齐拉西酮组治疗精神分裂症组,stroop色词测验中第3项色词测验治疗后成绩显著好于治疗前(t=3.48,P=0.00);阴性组、阳性组和混合组中的凝视点数,反应探索评分及D值与PANSS减分率呈显著正相关(r=0.49,0.54,0.51,P均〈O.05),其他各项认知测定治疗前后的改善均不明显。结论:眼动检测对某些精神分裂症的疗效具有一定的预测作用。 Objective To study the correlation between Exploratory eye movement examination (DEM2000) and therapeutic effects in patientswith schizophrenia .Methods: 18 negative (negative group), 20 other schizophrenic patients cminxed group) with ziprasidone for 8 weeks .and 28normal controls (control group ) were administered auditory Exploratory eye movement examination (DEM2000)Number of Eye Fixation (NEF),Responsive search Score(Rss). Results: The score of PANSS was declined obviously score evaluated before the treatment .AS to the comparisonof the cognitive function, patients in ziprasidone group improved greatly after treatment on third test of the stroop color word test (t=-3.48,p=0.00); The remaining cognitive tests were not improved greatly afer the treatment in ziprasidone groups .There were positive correlation betweenthe NEF RSS and D in negative group and positive group ,mixed group and PANSS subtractive score rate (r=0.49,0.54,0.51 all p〈0.05)Conclusion:DEM2000 can predict the effects of treatment in some patients with schizophrenia .
出处 《世界中医药》 CAS 2016年第B03期1490-1491,共2页 World Chinese Medicine
关键词 眼动检测 精神分裂症 齐拉西酮 认知功能 DEM2000 schizophrenia ziprasidone cognitive function
  • 相关文献

参考文献6

二级参考文献23

  • 1沈渔邨.精神病学[M].5版.北京:人民卫生出版社.2009:838.
  • 2Glassman AH. Clinical management of cardiovascular risks during treatment with psychotropic drugs. J Clin Psychiatry, 2002; 63 [Suppl, 9]: 12-17.
  • 3Casey DE,Zorn SH. The pharmacology of weigh gain with antipsychotics. J Clin Psychiatry, 2001; 62 [Suppl, 7]:4-10.
  • 4Emsley R, Oosthuizen P. The new and evolving pharmacotherapy of schizophrenia. Psychiat Clin North Am.2003; 26 (1): 141-163.
  • 5Hirschfeld RM. The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry, 2003; 64 [Suppl,8]: 15-21.
  • 6Stimmel GL, Guitierrez MA, Lee V. Ziprasidone : an atypical antipsychotic drug for the treatment of schizophrenia.Clinical Therapeutics, 2002; 24 (1): 21-37.
  • 7Kaye NS. Ziprasidone augmentation of clozapine in patients. J Clin Psychiatry, 2003; 64 (2): 215-216.
  • 8Ketter TA, Wang PW. The emerging differential role of GABAergic and antiglutamatergic agents in bipolar disorders. J Clin Psychiatry, 2003; 64 [Suppl, 3]: 15-20.
  • 9Nolan BP, Schulte JJ. Mania associated with initiation of ziprasidone. J Clin Psychiatry, 2003; 64 (3): 336.
  • 10McDougle CJ ,Stigler KA ,Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry; 2003; 64 [Suppl, 4]: 16-25.

共引文献90

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部